Matches in Nanopublications for { ?s ?p "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP225362.RAZXybDa_5rIRUBu8wiTIw5iowQ9PXu59DWhUJuq1j5LE130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225362.RAZXybDa_5rIRUBu8wiTIw5iowQ9PXu59DWhUJuq1j5LE130_provenance.
- assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1074217.RASQ0U02QBGjcXtJuwrMwmB1fw6HqEkBVDp0jy5Ru72Ro130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074217.RASQ0U02QBGjcXtJuwrMwmB1fw6HqEkBVDp0jy5Ru72Ro130_provenance.
- NP570455.RAqtR9grNJUD_53zbLXHvSVudzuOLjoNPLwQSgCmBoSIA130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570455.RAqtR9grNJUD_53zbLXHvSVudzuOLjoNPLwQSgCmBoSIA130_provenance.
- NP570669.RAn0gwih0trPncSAVHqUVgPQo5fTJpvLwbygFvLYcOC50130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570669.RAn0gwih0trPncSAVHqUVgPQo5fTJpvLwbygFvLYcOC50130_provenance.
- NP224913.RAvGYqVx8D8_JwdyRtmDmWvNI2VrQiwTCWa9Ukehw_t2k130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP224913.RAvGYqVx8D8_JwdyRtmDmWvNI2VrQiwTCWa9Ukehw_t2k130_provenance.
- NP1074216.RAu5_uySBrGMywZdyjYtpnO8qBxgmM-me5LcYUUL2sMls130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074216.RAu5_uySBrGMywZdyjYtpnO8qBxgmM-me5LcYUUL2sMls130_provenance.
- NP1074218.RA-76qwKX712TAmCamFBopBf3rDmrtZhvdLfmSz_tOnOk130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074218.RA-76qwKX712TAmCamFBopBf3rDmrtZhvdLfmSz_tOnOk130_provenance.
- NP1074221.RA0HPKSUWQxVcAam8KcHMsz0z-EtN1N5jNcGxymWck1O4130_assertion description "[MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074221.RA0HPKSUWQxVcAam8KcHMsz0z-EtN1N5jNcGxymWck1O4130_provenance.